Impact of tumor number on the efficacy of lenvatinib in borderline resectable hepatocellular carcinoma.

ABSTRACT:

Background

The global incidence of hepatocellular carcinoma (HCC) is steadily rising, and the disease is associated with poor survival outcomes. As a multicentric cancer with a high recurrence rate, surgical resection alone is often not sufficient for a curative treatment. This study aimed to identify factors that predict its efficacy in patients with HCC classified as borderline resectable according to the BR-HCC Expert Consensus 2023.

Methods

This study retrospectively analyzed 30 patients with borderline resectable HCC who were treated with Lenvatinib as their initial therapy. The study retrospectively examined the predictive factors for the disease control rate (DCR) following Lenvatinib treatment. A secondary objective was to evaluate the impact of the treatment on over

SUBMITTER: Chiba N 

PROVIDER: S-EPMC12494618 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature